|Chemical and physical data|
|Molar mass||357.530 g/mol|
|3D model (Jmol)||Interactive image|
Zenazocine (INN; WIN-42,964) is an opioid analgesic of the benzomorphan family which made it to phase II clinical trials before development was ultimately halted and it was never marketed. It acts as a partial agonist of the μ- and δ-opioid receptors, with less intrinsic activity at the former receptor and more at the latter receptor (hence, it behaves more antagonistically at the former and more agonistically at the latter), and produces antinociceptive effects in animal studies.
- Ward, S. J.; Pierson, A. K.; Michne, W. F. (1985). "Pharmacological profiles of tonazocine (Win 42156) and zenazocine (Win 42964)". Neuropeptides. 5 (4–6): 375–378. doi:10.1016/0143-4179(85)90032-0. PMID 2860595.
- Cotton, R.; James, R. (1985). "Chapter 3. Analgesics, Opioids and Opioid Receptors". In Bailey, D. M. Annual Reports in Medicinal Chemistry. 20. Academic Press. pp. 21–30. doi:10.1016/S0065-7743(08)61029-5. ISBN 978-0-12-040520-6.
See also: Peptide receptor modulators